Literature DB >> 33637063

Patients and family caregivers report high treatment expectations during palliative chemotherapy: a longitudinal prospective study.

Tine Ikander1,2,3,4,5, Stefan Starup Jeppesen6,7, Olfred Hansen6,7, Mette Raunkiær8,7, Karin Brochstedt Dieperink6,9,7.   

Abstract

BACKGROUND: When discussing treatment options and future care, it is important to understand the expectations of patients and family caregivers related to palliative chemotherapy and to identify patterns in patients' quality of life. The study aims were to evaluate differences in treatment expectations and quality of life between patients with thoracic cancer (non-small-cell lung cancer, small-cell lung cancer and mesothelioma) who were < 70 and ≥ 70 years of age and receiving palliative chemotherapy and to assess family caregivers' treatment expectations.
METHODS: A prospective longitudinal study included patients with thoracic cancer receiving outpatient palliative chemotherapy at a university hospital in Denmark and their family caregivers. Patients' treatment expectations and quality of life were assessed three times during treatment with a survey of treatment expectations and the Functional Assessment of Cancer Therapy - General questionnaire. Family caregivers' treatment expectations were assessed once.
RESULTS: A total of 48 patients and 36 family caregivers participated between 2018 and 2019. No statistically significant age-related differences in treatment expectations and quality of life were identified. 28% of patients aged < 70 years and 7% of those aged ≥70 years expected a cure. Among family caregivers, 36% expected a cure. Across both age groups, mean total quality of life scores significantly decreased from 73.2 at first palliative chemotherapy cycle to 70.5 at third cycle (p = 0.02). No meaningful changes were found in quality of life within either age group. A subgroup analysis found no significant between-group differences in quality of life. Mean physical well-being score for all patients decreased from 20.3 at first cycle to 18.4 at third cycle (p = 0.03) and mean emotional well-being score decreased from 15.4 at first cycle to 14.6 at third cycle (p = 0.04).
CONCLUSION: This study emphasizes the importance of initiating conversations about treatment expectations and paying attention to expectations that may differ by the age of the patient and between patients and family caregivers. Addressing treatment expectations among patients and family caregivers and monitoring quality of life among patients is important in clinical practice.

Entities:  

Keywords:  Family caregivers; Longitudinal studies; Lung neoplasms; Palliative care; Quality of life

Year:  2021        PMID: 33637063      PMCID: PMC7912463          DOI: 10.1186/s12904-021-00731-4

Source DB:  PubMed          Journal:  BMC Palliat Care        ISSN: 1472-684X            Impact factor:   3.234


  29 in total

1.  The analysis and interpretation of cognitive interviews for instrument development.

Authors:  Kathleen Knafl; Janet Deatrick; Agatha Gallo; Gwynne Holcombe; Marie Bakitas; Jane Dixon; Margaret Grey
Journal:  Res Nurs Health       Date:  2007-04       Impact factor: 2.228

2.  Patients' Hopes for Advanced Cancer Treatment.

Authors:  Jeremy DeMartini; Joshua J Fenton; Ronald Epstein; Paul Duberstein; Camille Cipri; Daniel Tancredi; Guibo Xing; Paul Kaesberg; Richard L Kravitz
Journal:  J Pain Symptom Manage       Date:  2018-09-25       Impact factor: 3.612

Review 3.  Geriatric oncology: challenges for the new century.

Authors:  L Balducci
Journal:  Eur J Cancer       Date:  2000-09       Impact factor: 9.162

4.  Measurement of health-related quality of life during chemotherapy - the importance of timing.

Authors:  Are Kristensen; Tora S Solheim; Tore Amundsen; Harald H Hjelde; Stein Kaasa; Sveinung Sørhaug; Bjørn H Grønberg
Journal:  Acta Oncol       Date:  2017-01-24       Impact factor: 4.089

5.  Patient beliefs that chemotherapy may be curative and care received at the end of life among patients with metastatic lung and colorectal cancer.

Authors:  Jennifer W Mack; Anne Walling; Sydney Dy; Anna Liza M Antonio; John Adams; Nancy L Keating; Diana Tisnado
Journal:  Cancer       Date:  2015-02-11       Impact factor: 6.860

6.  The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.

Authors:  Thomas A Hensing; Amy H Peterman; Michael J Schell; Ji-Hyun Lee; Mark A Socinski
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

7.  Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy.

Authors:  Mihaela A Popa; Kristie J Wallace; Antonella Brunello; Martine Extermann; Lodovico Balducci
Journal:  J Geriatr Oncol       Date:  2014-05-10       Impact factor: 3.599

8.  Trends in receiving chemotherapy for advanced cancer patients at the end of life.

Authors:  Hee Seung Lee; Kyeong Hyeon Chun; Dochang Moon; Hahn Kyu Yeon; Sanghoon Lee; SooHyeon Lee
Journal:  BMC Palliat Care       Date:  2015-03-13       Impact factor: 3.234

9.  Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer.

Authors:  N B Leighl; F A Shepherd; D Zawisza; R L Burkes; R Feld; J Waldron; A Sun; D Payne; A Bezjak; M H N Tattersall
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640

10.  Quality of life during chemotherapy in lung cancer patients: results across different treatment lines.

Authors:  L M Wintner; J M Giesinger; A Zabernigg; M Sztankay; V Meraner; G Pall; W Hilbe; B Holzner
Journal:  Br J Cancer       Date:  2013-10-03       Impact factor: 7.640

View more
  2 in total

1.  Understanding the experiences of older caregivers of patients with lung cancer during palliative chemotherapy in China: a qualitative study.

Authors:  Min Xue; Xiaoyun Chen; Haiyan Zhao; Yumei Zhao; Jing Li; Weijuan Chen
Journal:  Support Care Cancer       Date:  2022-06-28       Impact factor: 3.359

2.  Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus.

Authors:  A Carrato; L Cerezo; J Feliu; T Macarulla; E Martín-Pérez; R Vera; J Álvarez; J I Botella-Carretero
Journal:  Clin Transl Oncol       Date:  2021-08-07       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.